Sumitomo America Patent-Cliff Exposure & CMS Drug Spending Portfolio
Sumitomo America (US): 4 reconciled FDA prescription therapies (15.2% 2025 to 2030 cliff risk), $1.78B 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 4 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 15.2% |
| Primary Portfolio LOE Date | 2032-01-01 |
| 2024 CMS Total Public Spend | $1.78B |
| 2024 Medicare Part D Spend | $1.58B |
| 2024 Medicaid Spend | $202.0M |
| California HCAI SB 17 Filings | 15 WAC filings (max 21.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.